NASDAQ : HROW
Harrow, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 28.24 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.06B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.06B |
| Enterprise Value | 1.27B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 37.49M |
| Shares Outstanding | 37.49M |
| Shares Change (YoY) | +3.39% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 16.43% |
| Owned by Institutions (%) | 53.04% |
| Float | 28.93M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 22.14 |
| PS Ratio | 3.84 |
| Forward PS | 2.37 |
| PB Ratio | 69.64 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 211.06 |
| P/OCF Ratio | 169.33 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 4.62 |
| EV / EBITDA | 71.92 |
| EV / EBIT | n/a |
| EV / FCF | 254.00 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.24 |
| Quick Ratio | 2.00 |
| Debt / Equity | 20.26 |
| Debt / EBITDA | 15.70 |
| Debt / FCF | 59.96 |
| Interest Coverage | -0.12 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -116.07% |
| Return on Assets (ROA) | -0.45% |
| Return on Invested Capital (ROIC) | -1.19% |
| Return on Capital Employed (ROCE) | -0.87% |
| Weighted Average Cost of Capital (WACC) | 5.44% |
| Revenue Per Employee | $738,858 |
| Profits Per Employee | -$99,802 |
| Employee Count | 373 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 5.17 |
Taxes
| Measure | Value |
|---|
| Income Tax | 3.80M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -23.21% |
| 50-Day Moving Average | 32.86 |
| 200-Day Moving Average | 38.35 |
| Relative Strength Index (RSI) | 38.54 |
| Average Volume (20 Days) | 592,963 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.47M |
| Short Previous Month | 7.76M |
| Short % of Shares Out | 19.94% |
| Short % of Float | 25.84% |
| Short Ratio (days to cover) | 11.49 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 275.59M |
| Gross Profit | 201.96M |
| Operating Income | -2.75M |
| Pretax Income | -33.43M |
| Net Income | -37.23M |
| EBITDA | 17.72M |
| EBIT | -2.75M |
| Loss Per Share | -$1.00 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 85.32M |
| Total Debt | 300.74M |
| Net Cash | -215.43M |
| Net Cash Per Share | -$5.75 |
| Equity (Book Value) | 14.85M |
| Book Value Per Share | 0.41 |
| Working Capital | 127.14M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 6.25M |
| Capital Expenditures | -1.24M |
| Depreciation & Amortization | 20.46M |
| Net Borrowing | 62.47M |
| Free Cash Flow | 5.02M |
| FCF Per Share | $0.13 |
Margins
| Measure | Value |
|---|
| Gross Margin | 73.28% |
| Operating Margin | -1.00% |
| Pretax Margin | -12.13% |
| Profit Margin | -13.51% |
| EBITDA Margin | 6.43% |
| EBIT Margin | -1.00% |
| FCF Margin | 1.82% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.39% |
| Shareholder Yield | -3.39% |
| Earnings Yield | -3.54% |
| FCF Yield | 0.47% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $63.00 |
| Price Target Difference | 123.09% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 38.54% |
| EPS Growth Forecast (3Y) | 177.57% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Feb 8, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.55 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |